NFE2L2 and ovarian carcinoma: Nuclear factor erythroid 2-related factor 2 (NRF2) inhibition stands out as a potential strategy to elevate the labile iron pool (LIP), intensifying ferroptotic sensitivity in cancer cells that is clinically relevant to ovarian cancer [38].